Daniel Persky, MD

Associate Professor of Clinical Medicine

Short Bio: 

Dr. Persky serves as Associate Professor of Clinical Medicine at the University of Arizona College of Medicine.  He specializes in Internal Medicine and Hematology and Oncology.

Dr. Persky received his Bachelor's Degree from Harvard University and his medical degree from the Albert Einstein College of Medicine in New York.  He completed his internship and residency at the Mayo Graduate School of Medicine in Rochester, Minnesota, then returned to New York to complete a three-year fellowship in Medical Oncology and Hematology at Memorial Sloan-Kettering Cancer Center.

Dr. Persky is board certified by the American Board of Internal Medicine, subspeciality of Medical Oncology.

Clinical Information
Medical Oncologist
Clinical Focus: 

Lymphoid Malignancies

Clinical Practice Sites: 
The University of Arizona Cancer Center - North Campus
Research Information
Research Program: 
1. Therapeutic Development
Member Status: 
Associate Member
Selected Publications: 

1. Liu G, Grant WM, Persky D, Latham VM Jr, Singer RH, Condeelis J. Interaction of elongation factor 1 alpha with F-actin and beta-actin mRNA; implications for anchoring mRNA in cell protrusions. Mol Biol Cell 2002 Feb; 13(2):579-92.

 2. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D,  Ansell SM, Micallef IN, Markovic SN. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004 Feb;33(3):291-8.

 3. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ,  Persky D, Lacy MQ, Dispenzieri A, Snow DS, Markovic SN. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation  in multiple myeloma. Leukemia. 2004 Jun;18(6):1085-92.

 4. Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, and Miller TP. Effect of Adding Rituximab to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Patients with Limited Stage Aggressive B-Cell Lymphoma. A  Southwest Oncology Group Study 0014. J Clin Oncol. 2008 May 10;26(14):2258-63.

 5. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Gene expression predicts overall survival in paraffin embedded tissues of diffuse large B cell lymphoma treated with R-CHOP. Blood 2008 Oct 15; 112(8): 3425-33.  Epub 2008 Jun 10.

 6. Rkein AM, Harrigal C, Friedman AC, Persky DO, Krupinksi E.  Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Acad Radiol 2009 Feb:16(2):181-6.

 7. Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma 2009 Apr 15:1-8 [Epub ahead of print]

8. Persky DO, Moskowitz, CH, Filatov A, Saxena R, Haiyan C, Teruya-Feldstein. J. High dose Chemoradiotherapy and ASCT May Overcome the Prognostic Importance of Biologic Markers in Relapsed/Refractory Hodgkin’s Lymphoma. Applied IHC & Mol Immuno  Accepted 02/15/09

Bio sketch: 
Professional Information
Board Certifications: 

Board Certified by the American Board of Internal Medicine, subspecialty of Medical Oncology

Professional Affiliations: 

American College of Physicians

American Society of Hematology

American Society of Clinical Oncology

Academic Information
Memorial Sloan-Kettering Cancer Center
Mayo Graduate School of Medicine, Rochester, MN
Medical School: 
Albert Einstein College of Medicine, NY
Undergraduate School: 
Harvard University